Collaborative Home Visits to Reduce Hospital Readmissions and Improve Medication Use During Transitions of Care

Home Visits Clinical Trial

Official title:

COLLABORATIVE HOME VISITS TO REDUCE HOSPITAL READMISSIONS AND IMPROVE MEDICATION USE DURING TRANSITIONS OF CARE

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02087072
• Other study ID #: 2013H0185
• Status: Withdrawn
• Start date: October 2013
• Est. completion date: December 2014

Study information

• Verified date: September 2022
• Source: Ohio State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective is to develop a sustainable practice model emphasizing home visits by a collaborative physician and pharmacist team to decrease unplanned emergency department visits and hospital readmissions at 30 and 90 days for high-risk home bound patients. Secondary objectives include (1) tracking the number, type, and severity of adverse drug events (ADE) and potential adverse drug events (pADE) that occur following hospital discharge and (2) resolving any identified ADE and pADE within 7 days of hospital discharge.

Adult patients will be scheduled for a home visit by the Healthy at Home Columbus program at the time of hospital discharge. The home visit will occur within 7 days of hospital discharge and will consist of a complete hospital and medication review by a physician or nurse practitioner and a pharmacist (including all lab tests, imaging studies, medication changes, and proposed plan of care at the time of discharge). The investigators hypothesize these home visits will reduce 30 and 90 days hospital readmission rates and ED visits.

The number of emergency department visits and unplanned hospital readmissions will be tracked at 30 and 90 days following discharge from the hospitalization that led to study enrollment. A comparison cohort of patients discharged in the 12 months prior to study initiation will be used to compare the effectiveness of the home visit program. The number and type of adverse drug events (ADE) and potential adverse drug events (pADE) that occur during transitions of care will also be characterized. All ADE and pADE will be resolved during the initial home visit and will be classified based on severity. All ADE and pADE will be evaluated independently by two pharmacist reviewers; each reviewer will independently assign a severity rating to each ADE and pADE.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients discharged from the hospital in the last 7 days and with more than two chronic conditions and significant obstacles to accessing care in an office setting are eligible for study participation

Exclusion Criteria:

• Adult patients able to access care in an office setting.

• Adult patients discharged from the hospital greater than 7 days prior to the office visit.

Related Conditions & MeSH terms

• Home Visits
• Transitional Care Coordination

Intervention

Other:
• Collaborative visit with provider and pharmacist

Locations

Country	Name	City	State
United States	The Ohio State University Division of General Internal Medicine Martha Morehouse	Columbus	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
Ohio State University	American Society of Health-System Pharmacy Foundation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Number of drug related problems identified		30 days
Other	Type of drug related problems identified		30 days
Primary	Hospital Readmission		30 days
Secondary	Emergency Department Visit		30 days